Sito Bio(300583)

Search documents
赛托生物(300583.SZ)暂无生产适用于肝炎的制剂
Ge Long Hui· 2025-09-11 06:59
Group 1 - The company, Saito Bio (300583.SZ), stated on the interactive platform that it currently does not have any formulations suitable for hepatitis [1]
赛托生物跌3.87% 2017上市两募资共13亿
Zhong Guo Jing Ji Wang· 2025-08-28 08:50
Group 1 - The stock of Saito Bio (300583.SZ) closed at 16.39 yuan, with a decline of 3.87%, resulting in a total market capitalization of 3.109 billion yuan [1] - Saito Bio is currently in a state of breaking its initial public offering price, having been listed on the ChiNext board on January 6, 2017, with an initial offering price of 40.29 yuan per share [1] - The company raised a total of 1.0744 billion yuan through its initial public offering, with a net amount of 1.0256 billion yuan after deducting issuance costs [1][3] Group 2 - Saito Bio has conducted a non-public issuance of 11.6418 million shares at a price of 22.47 yuan per share, raising a total of 261.5904 million yuan [2] - After deducting underwriting and sponsorship fees of 7.8 million yuan, the net amount raised from this issuance was 251.9224 million yuan [2] - The total amount raised by Saito Bio since its listing amounts to 1.336 billion yuan [3]
赛托生物2025年中报简析:净利润同比下降498.8%
Zheng Quan Zhi Xing· 2025-08-26 23:09
Core Insights - The financial report of Saito Bio (300583) for the first half of 2025 shows a significant decline in net profit, down 498.8% year-on-year, with total revenue also decreasing by 10.39% [1] Financial Performance Summary - Total revenue for the first half of 2025 was 508 million yuan, a decrease from 567 million yuan in the same period of 2024, representing a decline of 10.39% [1] - The net profit attributable to shareholders was -52.69 million yuan, compared to a profit of 13.21 million yuan in the previous year, marking a decline of 498.8% [1] - The gross profit margin fell to 12.01%, down 53.45% year-on-year, while the net profit margin turned negative at -11.78%, a decrease of 614.8% [1] - Selling, administrative, and financial expenses totaled 68.58 million yuan, accounting for 13.51% of revenue, which is an 18.83% decrease from the previous year [1] - Earnings per share dropped to -0.28 yuan, a decline of 500% compared to the previous year [1] Changes in Financial Items - Right-of-use assets decreased by 84.9% due to a reduction in operating lease real estate business [3] - Lease liabilities saw a decline of 93.32%, also attributed to the decrease in operating lease real estate [3] - Other receivables decreased by 40.13% due to the timely recovery of export tax refunds [3] - Long-term deferred expenses were fully amortized, resulting in a 100% decrease [3] - Sales expenses decreased by 37.45% due to a reduction in the scope of consolidation following the sale of a foreign subsidiary [3] - Management expenses decreased by 32.13% due to both the sale of a foreign subsidiary and optimization of management processes [3] - Income tax expenses decreased by 60.99% due to a reduction in taxable income [3] Cash Flow and Debt Analysis - Net cash increase from cash and cash equivalents rose by 469.23%, driven by increased cash flow from financing activities [4] - The company has a cash flow situation that warrants attention, with cash and cash equivalents to current liabilities at only 32.36% [5] - The interest-bearing debt ratio has reached 26.27%, indicating a significant level of debt [5]
机构风向标 | 赛托生物(300583)2025年二季度已披露持仓机构仅3家
Xin Lang Cai Jing· 2025-08-26 01:12
Core Viewpoint - Saito Bio (300583.SZ) released its semi-annual report for 2025, indicating a stable increase in institutional investor holdings, reflecting growing confidence in the company [1] Group 1: Institutional Holdings - As of August 25, 2025, three institutional investors disclosed holdings in Saito Bio A-shares, totaling 43.3048 million shares, which represents 22.83% of the total share capital [1] - The institutional investors include Shandong Runxin Investment Co., Ltd., Huaan CSI 1000 Index Enhanced A, and Huaan CSI 500 Index Enhanced A [1] - Compared to the previous quarter, the total institutional holding percentage increased by 0.01 percentage points [1] Group 2: Public Fund Disclosures - During this period, two new public funds were disclosed compared to the previous quarter, namely Huaan CSI 1000 Index Enhanced A and Huaan CSI 500 Index Enhanced A [1]
山东赛托生物科技股份有限公司2025年半年度报告摘要
Shang Hai Zheng Quan Bao· 2025-08-25 21:30
Group 1 - The company has approved a profit distribution plan, proposing a cash dividend of 0.1 yuan per 10 shares based on a total of 189,702,126 shares, with no bonus shares issued and no capital reserve conversion [3] - There have been no changes in the controlling shareholder or actual controller during the reporting period [5][6] - The company's operating conditions have not undergone significant changes during the reporting period [7]
赛托生物: 关于2025年半年度利润分配预案的公告
Zheng Quan Zhi Xing· 2025-08-25 16:42
Group 1 - The company reported a net profit attributable to ordinary shareholders of -52,687,137.35 yuan for the first half of 2025, while the parent company achieved a net profit of 2,477,250.60 yuan [1] - As of June 30, 2025, the cumulative net profit available for distribution to investors in the consolidated financial statements was 224,112,175.52 yuan [1] - The proposed profit distribution plan is to distribute 1.18 yuan per share (including tax) to all shareholders based on the total share capital of 189,702,126 shares, with no bonus shares or capital reserve conversion [2] Group 2 - The profit distribution plan complies with relevant regulations including the Company Law and accounting standards, ensuring legality, compliance, and reasonableness [2] - The implementation of the profit distribution plan is subject to approval at the company's first extraordinary general meeting of 2025, indicating a level of uncertainty [2]
赛托生物(300583.SZ):上半年净亏损5268.71万元
Ge Long Hui A P P· 2025-08-25 12:10
格隆汇8月25日丨赛托生物(300583.SZ)公布2025年半年度报告,上半年公司实现营业收入5.08亿元,同 比下降10.39%;归属于上市公司股东的净利润-5268.71万元,同比盈转亏;归属于上市公司股东的扣除 非经常性损益的净利润-5348.16万元;基本每股收益-0.28元。 ...
赛托生物发布上半年业绩,由盈转亏5268.71万元
智通财经网· 2025-08-25 12:04
Group 1 - The core viewpoint of the article is that Saito Bio (300583.SZ) reported a decline in revenue and incurred a net loss for the first half of 2025 [1] - The company achieved operating revenue of 508 million yuan, representing a year-on-year decrease of 10.39% [1] - The net loss attributable to shareholders of the listed company was 52.6871 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 53.4816 million yuan [1] - The basic loss per share was 0.28 yuan [1]
赛托生物(300583.SZ)发布上半年业绩,由盈转亏5268.71万元
智通财经网· 2025-08-25 11:53
智通财经APP讯,赛托生物(300583.SZ)发布2025年半年度报告,报告期内,公司实现营业收入5.08亿 元,同比下降10.39%。归属于上市公司股东净亏损5268.71万元。归属于上市公司股东的扣除非经常性 损益净亏损5348.16万元。基本每股亏损0.28元。 ...
赛托生物(300583) - 公司章程修订案(2025年8月)
2025-08-25 10:31
山东赛托生物科技股份有限公司 公司章程修订案 公司于 2025 年 8 月 22 日召开第四届董事会第九次会议审议通过了《关于修订<公司章程>的议案》。具体修订情况如下: | 序 | 原章程内容 | 修订后章程内容 | | --- | --- | --- | | 号 | | | | | 第一条 为维护公司、股东和债权人的合法权益,规范公司的组织和行 | 第一条 为维护山东赛托生物科技股份有限公司(以下简称"公司")、 | | | | 股东、职工和债权人的合法权益,规范公司的组织和行为,根据《中华 | | 1 | 为,根据《中华人民共和国公司法》(以下简称《公司法》)、《中华 | 人民共和国公司法》(以下简称《公司法》)、《中华人民共和国证券 | | | 人民共和国证券法》(以下简称《证券法》)、《中国共产党党章》(以 | | | | 下简称《党章》)和其他有关规定,制订本章程。 | 法》(以下简称《证券法》)《中国共产党章程》和其他有关规定,制 | | | | 订本章程。 | | | 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司(以 | 第二条 公司系依照《公司法》和其他有关规定成立的股份有限 ...